Literature DB >> 12446610

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.

Ricardo Rocha1, Cynthia L Martin-Berger, Pochang Yang, Rachel Scherrer, John Delyani, Ellen McMahon.   

Abstract

We studied the role of aldosterone (aldo) in myocardial injury in a model of angiotensin (Ang) II-hypertension. Wistar rats were given 1% NaCl (salt) to drink and randomized into one of the following groups (n = 10; treatment, 21 d): 1) vehicle control (VEH); 2) Ang II infusion (25 ng/min, sc); 3) Ang II infusion plus the selective aldo blocker, eplerenone (epl, 100 mg/kg.d, orally); 4) Ang II infusion in adrenalectomized (ADX) rats; and 5) Ang II infusion in ADX rats with aldo treatment (20 micro g/kg.d, sc). ADX rats received also dexamethasone (12 micro g/kg.d, sc). Systolic blood pressure increased with time in all treatment groups except the VEH group (VEH, 136 +/- 6; Ang II/NaCl, 203 +/- 12; Ang II/NaCl/epl, 196 +/- 10; Ang II/NaCl/ADX, 181 +/- 7; Ang II/NaCl/ADX/aldo, 236 +/- 8 mm Hg). Despite similar levels of hypertension, epl and ADX attenuated the increase in heart weight/body weight induced by Ang II. Histological examination of the hearts evidenced myocardial and vascular injury in the Ang II/salt (7 of 10 hearts with damage, P < 0.05 vs. VEH) and Ang II/salt/ADX/aldo groups (10 of 10 hearts with damage, P < 0.05). Injury included arterial fibrinoid necrosis, perivascular inflammation (primarily macrophages), and focal infarctions. Vascular lesions were associated with expression of the inflammatory mediators cyclooxygenase 2 (COX-2) and osteopontin in the media of coronary arteries. Myocardial injury, COX-2, and osteopontin expression were markedly attenuated by epl treatment (1 of 10 hearts with damage, P < 0.05 vs. Ang II/salt) and adrenalectomy (2 of 10 hearts with damage, P < 0.05 vs. Ang II/salt). Our data indicate that aldo plays a major role in Ang II-induced vascular inflammation in the heart and implicate COX-2 and osteopontin as potential mediators of the damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446610     DOI: 10.1210/en.2002-220120

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  68 in total

Review 1.  Inflammation and therapy for hypertension.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

3.  The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.

Authors:  Nicola C Edwards; Richard P Steeds; Colin D Chue; Paul M Stewart; Charles J Ferro; Jonathan N Townend
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 4.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 5.  Pleiotropic effects of cardiac drugs on healing post-MI. The good, bad, and ugly.

Authors:  Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2008-02-07       Impact factor: 4.214

6.  PKCδ Mediates Mineralocorticoid Receptor Activation by Angiotensin II to Modulate Smooth Muscle Cell Function.

Authors:  Qing Lu; Ana P Davel; Adam P McGraw; Sitara P Rao; Brenna G Newfell; Iris Z Jaffe
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

Review 7.  Mineralocorticoid receptor antagonists and hypertension: is there a rationale?

Authors:  Olga Gumieniak; Gordon H Williams
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

8.  Aldosterone-receptor antagonism and end-stage renal disease.

Authors:  Niall McLaughlin; Todd W B Gehr; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

Review 9.  Aldosterone in vascular and metabolic dysfunction.

Authors:  James M Luther
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-01       Impact factor: 2.894

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.